ATXS Astria Therapeutics Inc
Price (delayed)
$6.81
Market cap
$384.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.17
Enterprise value
$309.06M
Highlights
Astria Therapeutics's equity has surged by 85% YoY
ATXS's quick ratio is up by 9% YoY
The company's EPS rose by 9% QoQ but it fell by 2.4% YoY
The net income has dropped by 83% year-on-year and by 7% since the previous quarter
Key stats
What are the main financial stats of ATXS
Market
Valuations
Earnings
Shares outstanding
56.43M
Market cap
$384.32M
Enterprise value
$309.06M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.12
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$116.17M
Net income
-$100.04M
EBIT
-$100.04M
EBITDA
-$100.04M
Free cash flow
-$94.43M
Per share
Balance sheet
Liquidity
EPS
-$2.17
EPS diluted
-$2.17
Free cash flow per share
-$1.63
Book value per share
$6.05
Revenue per share
$0
TBVPS
$6.25
Total assets
$361.64M
Total liabilities
$19.99M
Debt
$5.64M
Equity
$341.65M
Working capital
$336.14M
Debt to equity
0.02
Current ratio
22.38
Quick ratio
21.9
Net debt/EBITDA
0.75
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.4%
Return on equity
-30.8%
Return on invested capital
-49.7%
Return on capital employed
-28.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATXS stock price
How has the Astria Therapeutics stock price performed over time
Intraday
-0.15%
1 week
-3.54%
1 month
-10.04%
1 year
-47.53%
YTD
-23.83%
QTD
-23.83%
Financial performance
How have Astria Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$116.17M
Net income
-$100.04M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 84% year-on-year and by 8% since the previous quarter
The net income has dropped by 83% year-on-year and by 7% since the previous quarter
Growth
What is Astria Therapeutics's growth rate over time
Valuation
What is Astria Therapeutics stock price valuation
P/E
N/A
P/B
1.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 9% QoQ but it fell by 2.4% YoY
Astria Therapeutics's equity has surged by 85% YoY
The P/B is 30% lower than the last 4 quarters average of 1.6 and 14% lower than the 5-year quarterly average of 1.3
Efficiency
How efficient is Astria Therapeutics business performance
The ROIC has increased by 22% YoY and by 20% QoQ
Astria Therapeutics's return on equity has decreased by 15% YoY but it has increased by 6% QoQ
ATXS's ROA is down by 14% YoY but it is up by 6% QoQ
Dividends
What is ATXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATXS.
Financial health
How did Astria Therapeutics financials performed over time
ATXS's total liabilities has soared by 113% year-on-year but it is down by 4.4% since the previous quarter
ATXS's total assets has soared by 87% YoY
Astria Therapeutics's debt is 98% lower than its equity
Astria Therapeutics's equity has surged by 85% YoY
Astria Therapeutics's debt has decreased by 2.6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.